Study confirms heart failure risks in Actos, Avandia

09/27/2007 | MSNBC

The latest in a series of studies on diabetes drugs Actos and Avandia has confirmed the treatments' link to an increased risk of heart failure, notably in patients with a history of heart disease and congestive cardiac failure. Takeda Pharmaceutical Co.'s Actos and GlaxoSmithKline's Avandia, however, did not appear to increase the risk of cardiac-related death, according to the study.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX